(Q35964242)

11 August 2017

1 reference

title

New approaches in the treatment of myelofibrosis (English)

1 reference

11 August 2017

4

Hagop Kantarjian

1 reference

11 August 2017

5

Srdan Verstovsek

1 reference

11 August 2017

1

Bryan T Hennessy

1 reference

11 August 2017

3

Francis J Giles

1 reference

11 August 2017

Deborah A Thomas

2

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

11 August 2017

1 reference

11 August 2017

volume

103

1 reference

11 August 2017

issue

1

1 reference

11 August 2017

page(s)

32-43

1 reference

Involvement of the fibrogenic cytokines, TGF-beta and bFGF, in the pathogenesis of idiopathic myelofibrosis

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

Myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Diagnostic and clinical relevance of the number of circulating CD34+ cells in myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Primary (essential) thrombocythemia versus initial (hyperplastic) stages of agnogenic myeloid metaplasia with thrombocytosis--a critical evaluation of clinical and histomorphological data

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Pathogenesis and management of idiopathic myelofibrosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Spontaneous STAT5 activation induces growth factor independence in idiopathic myelofibrosis: possible relationship with FKBP51 overexpression.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Elevated thrombopoietin levels in patients with myelofibrosis may not be due to enhanced production of thrombopoietin by bone marrow

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Splenic irradiation in myelofibrosis with myeloid metaplasia: a review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Suramin toxicity and efficacy in agnogenic myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Thalidomide treatment in myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Thalidomide in agnogenic and secondary myelofibrosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Thalidomide for the treatment of idiopathic myelofibrosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Sequential combination of thalidomide and erythropoietin determines transfusion independence and disease control in idiopathic myelofibrosis previously insensitive to both drugs used as single agents.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Immunomodulation by thalidomide and thalidomide analogues

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

The syndrome of anorexia-cachexia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

The role of cytokines in cancer-related fatigue

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

TNF-alpha targeted therapeutic approaches in patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Thalidomide for distressing night sweats in advanced malignant disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Thalidomide for night sweats in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

ARG tyrosine kinase activity is inhibited by STI571.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

RETRACTED: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Platelet factor 4 enhances generation of activated protein C in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

SU6668 in idiopathic myelofibrosis--a rational therapeutic approach targeting several tyrosine kinases of importance for the myeloproliferation and the development of bone marrow fibrosis and angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

The role of interferon-alpha in the treatment of idiopathic myelofibrosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Antithrombin Phe229Leu: a new homozygous variant leading to spontaneous antithrombin polymerization in vivo associated with severe childhood thrombosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Transplant strategies for idiopathic myelofibrosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. French Society of Bone Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Allogeneic hematopoietic stem cell transplantation for myelofibrosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Stem cell transplantation for myelofibrosis: a report from two Canadian centers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation in myeloid diseases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: evidence for a 'graft vs. myelofibrosis' effect

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Morbidity after brachytherapy for prostate adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20752

7 January 2021

Identifiers

DOI

10.1002/CNCR.20752

1 reference

11 August 2017

1 reference